Mesenchymal Stromal Cells as Rescue Therapy for Refractory Chronic Lung Allograft Dysfunction: Analysis of Immunoregulatory Effects In Vitro and Preliminary Data of Safety In Vivo

Purpose: Mesenchymal stromal cells (MSCs) have been reported as a promising therapy for CLAD due to their immunomodulatory and tolerogenic properties. To assess MSC immunoregulatory/anti-remodeling effects in vitro and the safety profile in vivo we: 1) assessed bone marrow-derived MSC (BMSC) activity on normal precision cut lung slices (PCLS) cultures and 2) we monthly administered 1 x 106 BMSC/Kg BW to end stage CLAD patients who had previously failed several treatment lines including azithromycin, ECP and montelukast.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research